Drug Profile
Cytokine-induced killer cell therapy - Boston 3T Biotechnologies
Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Boston 3T Biotechnologies
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for preclinical development in Cancer in USA
- 01 Aug 2016 Preclinical development is ongoing in USA
- 17 Jan 2014 Preclinical trials in Cancer in USA (unspecified route)